Who asks about TB-500 and the questions they bring

Searches start with a soft-tissue injury. The honest answer starts with what the human evidence does and does not show.

TL;DR

• TB-500 searches typically follow a tendon or ligament injury, or a podcast mention of recovery peptides.
• The repeating question is whether animal repair data translates to humans — the answer is incomplete.
• Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness.

What it is

TB-500 is a synthetic peptide that copies a 17-amino-acid section of thymosin beta-4 (in plain English: a small repair protein the body makes naturally). Researchers use the fragment because it appears to carry the active region of the larger protein (Goldstein et al., Annals of the New York Academy of Sciences, 2012).

How it works

Think of the body's repair process as a road crew responding to a pothole. TB-500 has been linked, in animal research, to two pieces of that work: helping form new small blood vessels and helping repair cells move toward an injury site. The mechanism comes from rats, mice, and cell studies. Human trial data is limited.

Who asks about it

Three groups usually arrive at this search. First, athletes and active adults dealing with a stubborn tendon or ligament. Second, post-surgery patients who want to know about recovery options. Third, people reading about longevity peptides who want to understand where TB-500 fits. The question is almost always practical: does it work in people, and can I legally get it?

What the research says

Published reviews describe effects on tendon repair, wound healing, and cardiac tissue models in animals (Goldstein et al., 2012). Human evidence is much thinner. Anyone considering TB-500 should know that line — it shapes every honest conversation a physician would have about it.

What to know before considering it

The regulatory reality matters most right now. As of September 2026, FDA has not made a final decision on TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding TB-500 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. Talk through that regulatory status before any side-effect or dosing question.

The Halftime POV

We will not pretend the animal story is a human story. The animal data is consistent. The human data is mostly still ahead. And FDA's final decision is still pending. We would rather say that clearly than dress up rodent results as a sure thing.

---

Related reading:

• TB-500 (thymosin beta-4): what this repair peptide is
• How TB-500 promotes angiogenesis and tissue healing
• Category 1 vs Category 2 peptides: the access framework

---

FAQ

Q: Who searches for TB-500? A: Mostly people nursing a soft-tissue injury — a tendon, a ligament, a stubborn shoulder — and people who heard about it on a recovery or longevity podcast. The shared question is whether the animal data carries over to humans.

Q: Is TB-500 the same as thymosin beta-4? A: TB-500 is a synthetic 17-amino-acid fragment of thymosin beta-4 (in plain English: the active piece of a larger repair protein the body makes). The fragment carries the part used in published research.

Q: Is TB-500 FDA-approved? A: No. TB-500 is not FDA-approved. As of September 2026, FDA has not made a final decision on TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding TB-500 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action.

---

Disclaimer

As of September 2026, FDA has not made a final decision on TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding TB-500 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.

Get started

We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.

---

Sources

• Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Annals of the New York Academy of Sciences, 2012.
• FDA Category 1 and Category 2 Bulk Drug Substances 503A list.

---

This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.